T1DNCT07836673
Pre-Exercise Whey and Pea Protein in Adolescents With Type 1 Diabetes
A study testing low whey protein, moderate whey protein and low Pea protein in people with T1D and T1DM, run by University of Jordan.
Trial summary
The goal of this clinical trial is to learn whether drinking whey protein or pea protein before exercise affects blood sugar levels and appetite in adolescents with type 1 diabetes. The study will also compare two different amounts of each type of protein. Read more about this study
- Who is it for?
- Ages 12 to 18 years
- What is being tested?
- low whey protein, moderate whey protein and low Pea protein
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 1 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Male and female adolescents with T1D
- Age: 12-18 years
- T1D duration ≥ 1 year and HbA1c <10%
- BMI-for Age- z-score between -2 and +2
- Able to complete 45 min moderate-intensity aerobic exercise
- Using CGM or willing / able to wear study CGM
- Using multiple daily injections
Who cannot join
- Medical comorbidities (celiac disease and thyroid disease),
- Diabetes complications or gastroparesis,
- milk protein allergy or eating disorders,
- severe hypo/ diabetic ketoacidosis in the past 3 months
- Age: <12 or > 18 years
- T1D duration < 1 year or HbA1c ≥10%
Show all 10Show fewer
- BMI -for Age- z-score < -2 or > +2
- Unable to exercise safely (physical limitations, intellectual disability, autism, mental health conditions)
- Not using/willing/able to use CGM
- Using once daily/mixed insulin regimens
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effects of Pre-Exercise Whey and Pea Protein Intake on Glycemic Responses and Postprandial Appetite During and After Moderate-Intensity Aerobic Exercise in Jordanian Adolescents With Type 1 Diabetes: A Randomized Crossover Trial.
The goal of this clinical trial is to learn whether drinking whey protein or pea protein before exercise affects blood sugar levels and appetite in adolescents with type 1 diabetes. The study will also compare two different amounts of each type of protein.
The main questions this study aims to answer are:
Read more
- Does drinking whey or pea protein before exercise affect blood sugar levels during and after moderate-intensity exercise?
- Does the amount of protein consumed before exercise affect blood sugar levels?
- Does whey or pea protein affect feelings of hunger, fullness, and satiety after exercise?
Researchers will compare four conditions: a low and moderate amount of whey protein and a low and moderate amount of pea protein. Each participant will complete all four conditions on separate study visits, allowing researchers to compare the effects within the same person.
Participants will:
- Drink a protein beverage 45 min before exercise.
- Complete 45 min moderate-intensity aerobic exercise under supervision.
- Wear a continuous glucose monitor to measure blood sugar levels during and after exercise.
- Report their feelings of hunger, fullness, and satiety at several times during the study.
- Follow the same general food, physical activity, and diabetes management instructions before each study visit.
The study may help researchers understand whether the type and amount of protein consumed before exercise can help manage blood sugar levels and appetite around exercise in adolescents with type 1 diabetes.
- Being tested
- low whey protein, moderate whey protein, low Pea protein, Moderate Pea protein
- Keywords
- RCT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
low whey proteinDietary supplement
Participants will consume a whey protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.
moderate whey proteinDietary supplement
Participants will consume a whey protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.
low Pea proteinDietary supplement
Participants will consume a pea protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.
Moderate Pea proteinDietary supplement
Participants will consume a pea protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.
| Study group | Role | What they receive |
|---|---|---|
| low whey protein | Experimental | Participants will consume a whey protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise. Receives: Dietary Supplement: low whey protein |
| moderate whey protein | Experimental | Participants will consume a whey protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise. Receives: Dietary Supplement: moderate whey protein |
| low pea protein | Experimental | Not described Receives: Dietary Supplement: low Pea protein |
| moderate pea protein | Experimental | Not described Receives: Dietary Supplement: Moderate Pea protein |
What is being measured
The primary outcome is the main question the study is designed to answer.
Continuous blood glucose levels using CGM "FreeStyle Libre 2 sensor"
Measured: 3 hours
Secondary outcomes (1)
postprandial appetite using VAS
Measured: 3 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for T1DStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Jordan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sondos Al-Obaidi, University of Jordan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07836673
- Sponsor's protocol ID
- UJ-T1D-PRO-2026
- Other IDs
- UJ IRB Approval Number
- Status last verified
- Sep 2026
- First submitted
- 10 Sep 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Pre-Exercise Whey and Pea Protein Intake on Glycemic Responses and Postprandial Appetite During and After Moderate-Intensity Aerobic Exercise in Jordanian Adolescents With Type 1 Diabetes: A Randomized Crossover Trial.
- ClinicalTrials.gov ID
- NCT07836673
- Acronym / sponsor ID
- UJ-T1D-PRO-2026
- Keywords
- RCT
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of JordanUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Mar 2027 (estimated)
- First posted
- 23 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether drinking whey protein or pea protein before exercise affects blood sugar levels and appetite in adolescents with type 1 diabetes. The study will also compare two different amounts of each type of protein.
The main questions this study aims to answer are:
- Does drinking whey or pea protein before exercise affect blood sugar levels during and after moderate-intensity exercise?
- Does the amount of protein consumed before exercise affect blood sugar levels?
- Does whey or pea protein affect feelings of hunger, fullness, and satiety after exercise?
Researchers will compare four conditions: a low and moderate amount of whey protein and a low and moderate amount of pea protein. Each participant will complete all four conditions on separate study visits, allowing researchers to compare the effects within the same person.
Participants will:
- Drink a protein beverage 45 min before exercise.
- Complete 45 min moderate-intensity aerobic exercise under supervision.
- Wear a continuous glucose monitor to measure blood sugar levels during and after exercise.
- Report their feelings of hunger, fullness, and satiety at several times during the study.
- Follow the same general food, physical activity, and diabetes management instructions before each study visit.
The study may help researchers understand whether the type and amount of protein consumed before exercise can help manage blood sugar levels and appetite around exercise in adolescents with type 1 diabetes.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| low whey protein | Experimental | Dietary Supplement: low whey proteinParticipants will consume a whey protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise. |
| moderate whey protein | Experimental | Dietary Supplement: moderate whey proteinParticipants will consume a whey protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise. |
| low pea protein | Experimental | Dietary Supplement: low Pea protein |
| moderate pea protein | Experimental | Dietary Supplement: Moderate Pea protein |
Who may qualify
- Ages
- 12 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (7 listed)
- Male and female adolescents with T1D
- Age: 12-18 years
- T1D duration ≥ 1 year and HbA1c <10%
- BMI-for Age- z-score between -2 and +2
- Able to complete 45 min moderate-intensity aerobic exercise
Key exclusion criteria (10 listed)
- Medical comorbidities (celiac disease and thyroid disease),
- Diabetes complications or gastroparesis,
- milk protein allergy or eating disorders,
- severe hypo/ diabetic ketoacidosis in the past 3 months
- Age: <12 or > 18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| low whey proteinParticipants will consume a whey protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise. | Dietary supplement | low whey protein |
| moderate whey proteinParticipants will consume a whey protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise. | Dietary supplement | moderate whey protein |
| low Pea proteinParticipants will consume a pea protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise. | Dietary supplement | low pea protein |
| Moderate Pea proteinParticipants will consume a pea protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise. | Dietary supplement | moderate pea protein |
Primary outcome
Continuous blood glucose levels using CGM "FreeStyle Libre 2 sensor"
Time frame: 3 hours
1 secondary outcome
postprandial appetite using VAS
Time frame: 3 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for T1D
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Active, not recruitingPhase 4
Diabetes in African Youth
type1diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing low whey protein, moderate whey protein and low Pea protein in people with T1D and T1DM, run by University of Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sondos Alobaidi (00962796329336, sondosalobaidi@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Continuous blood glucose levels using CGM "FreeStyle Libre 2 sensor" (time frame: 3 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.